Exploring the educational needs for severe immune-related adverse events of PD-1/PD-L1 inhibitors in advanced lung cancer: A single-center observational study.

Content Provider	Europe PMC
Author	Aso, Sakiko Kawamura, Nao Yanagida, Hideki Nakajima, Kazuko Ishikawa, Hiroshi Omori, Shota Murakami, Haruyasu Takahashi, Toshiaki Naito, Tateaki
Copyright Year	2022
Abstract	ObjectiveWith the expanded use of immunotherapy in medical oncology, effective patient education regarding immune-related adverse events (irAEs) is crucial for oncology nursing. Therefore, this study aimed to identify educational needs for preventing unscheduled hospitalizations due to severe irAEs.MethodsWe retrospectively reviewed the medical records of 159 consecutive patients with lung cancer who received programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors in 2020. We evaluated the frequency, severity, and unscheduled hospitalization due to irAEs based on the PD-1/PD-L1 inhibitor use. Educational needs were assessed based on initial symptoms, reporters, telephone consultation, and the time lag between symptom onset and hospital visit.ResultsAmong 159 patients evaluable for irAEs, 73 (45.9%) experienced 91 irAEs during the study period. Seventeen patients (10.7%) required unscheduled hospitalization due to severe irAEs after a median duration of 4.1 days from symptom onset, and 52.9% visited hospitals after telephone consultations from caregivers. Pneumonitis (10 events) was the most frequent irAE requiring hospitalization, followed by adrenal insufficiency (three events). The type and severity of irAEs varied based on PD-1/PD-L1 inhibitor use.ConclusionsThe frequency of severe irAEs requiring hospitalization was high in patients who received PD-1/PD-L1 inhibitors for advanced lung cancer. The early detection of severe irAEs may be possible through education focusing on common irAEs that are potentially severe. Patients and caregivers should be aware of the importance of reporting slight changes in symptoms after PD-1/PD-L1 therapy initiation in a timely manner. Healthcare professionals need to acknowledge common irAEs and be qualified to implement systematic telephone triage of irAEs.
Related Links	https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC9440266&blobtype=pdf
ISSN	23475625
Journal	Asia-Pacific Journal of Oncology Nursing [Asia Pac J Oncol Nurs]
Volume Number	9
DOI	10.1016/j.apjon.2022.100076
PubMed Central reference number	PMC9440266
Issue Number	8
PubMed reference number	36065289
e-ISSN	23496673
Language	English
Publisher	Elsevier
Publisher Date	2022-04-28
Access Restriction	Open
Rights License	This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). © 2022 The Authors
Subject Keyword	Caregivers Programmed cell death-1/programmed death-ligand 1 inhibitor Immune-related adverse events Patient education Telephone triage Neoplasms
Content Type	Text
Resource Type	Article
Subject	Oncology (nursing) Oncology